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ABSTRACT 
 
Back ground: Worldwide diabetes mellitus is no more an epidemic; rather it has 
turned into a pandemic health hazard. Association of obesity in type 2 diabetes 
mellitus is an established fact. This association could be partly mediated by 
altered secretion of adipokines by adipose tissue. Among all adipokines, 
adiponectin has been considered as an important factor in obesity induced insulin 
resistance. This new hormone produced exclusively by adipocytes differs from its 
predecessors in at least one important feature. While all of the other adipose 
tissue derived hormones related to insulin resistance are increased in obesity, 
adiponectin production and concentration actually decreases in obese subjects. 
Objective: the study was taken up to investigate the relationship between 
adiponectin in obese and non obese type 2 diabetes, and also to find out the 
correlation between adiponectin and serum lipids in urban south Indian 
population. Method: The cases chosen for the study group were already 
diagnosed cases of type 2 diabetes mellitus undergoing treatment. All subjects 
were interviewed regarding a full medical history that included age, sex, 
occupation, duration and family history of diabetes mellitus. The general physical 
examination procedure included measurement of height, weight, waist 
circumference and hip circumference. The biochemical parameters such as fasting 
plasma glucose, serum adiponectin, HDL and triglyceride were measured. Result: 
The reduction of serum adiponectin in study group was highly significant as 
compared to control group but its difference between the two subgroups divided 
based on BMI did not give a statistically significant result. But on correlation of 
BMI with adiponectin in study group, the correlation co-efficient was found to 
statistically highly significant. Similar correlation of waist-hip ratio (W/H) with 
adiponectin did not give a significant result. Conclusion: Adiponectin is lowered in 
obese non-diabetics affecting lipid metabolism showed by increase of LDL and TG 
and decrease of HDL. In obese diabetics adiponectin is high but dyslipidemia is 
still present possibly due to improper function of existing serum adiponectin. 
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INTRODUCTION 
Diabetes mellitus (DM) is a metabolic disorder characterized 
by defect in secretion, action or both of insulin resulting in 
chronic hyperglycemia with disturbance of carbohydrate, fat 
and protein metabolism. DM and obesity are closely 
interrelated in terms of pathogenesis and pathophysiology. 
Moreover, the prevention and control of these diseases have 
become prominent public health issues. Both DM and obesity 
result in vascular complications, such as coronary artery 
disease, cerebrovascular disease, and peripheral vascular 
disease, caused by arteriosclerosis. Obesity is defined as an 
increase in body fat mass. Visceral fat plays a more important 
role in a variety of metabolic abnormalities associated with 
obesity than subcutaneous fat and that increases in visceral 
fat both raise concentrations of hepatic portal blood free 
fatty acids and reduce insulin sensitivity [1]. While it has long 
been apparent that obesity is a major risk factor for type 2 
diabetes, it has recently been appreciated that adipose 
tissue, in addition to its role as an energy reservoir, 
modulates energy metabolism via secretion of circulating 
adipocytokines. Variety of adipocytokines including leptin, 
adipsin and tumor necrosis factor etc are produced by 
adipose tissue. Adiponectin, recently identified most 
abundant among them is a 30 kDa protein. It plays an 
important role in the regulation of glucose and lipid 
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metabolism [2, 3].   Adiponectin increases insulin sensitivity 
and improves glucose tolerance. Plasma adiponectin 
concentrations are positively correlated with whole-body 
insulin sensitivity. Adiponectin is found to be antidiabetic, 
anti-atherosclerotic and it also plays an important role in 
inflammation [4, 5]. Because of various metabolic effects of 
adiponectin, this study was designed to find out variation of 
adiponectin in obese and non obese type 2 diabetic patients 
and relation of adiponectin with lipid profile in type 2 
diabetic patients.  
The aim of the present work was to study the adiponectin 
concentration between obese and non-obese diabetic and 
non diabetic and also association of plasma adiponectin 
levels and lipid profile in type-2 diabetic patients in urban 
south Indian population.  
METHODOLOGY 
Study design: The present study is analytical case - control 
study  
Place of research: The study was conducted at Sri 
Ramachandra Medical College & Research Institute. 
Ethical approval: Written informed consent was obtained from 
each participant before commencement of the study. The 
study was performed in agreement with considerations as 
recommended by the Institutional Ethical Committee, Sri 
Ramachandra Medical College and Research Institute. 
Inclusion criteria:  ages ranging between 40 and 70 years 
including both genders were stratified according to diabetes 
mellitus and obesity into two categories each. 
1) In the first category, the subjects were divided into two 
groups as diabetic / cases (n=110) and non diabetic / 
control (n=50) 
2) In the second category, both the case and control group 
were further subdivided as obese (BMI> 25 Kg/m2) and 
non obese (BMI < 25Kg/m2) respectively. 
Exclusion criteria: Type 1 diabetes mellitus, gestational 
diabetes, any other cause of glucose intolerance, malignancies 
Sample size: A total of 160 subjects  
Grouping: The control group consisted of 50 normal healthy 
individuals and the study group comprised of 110 known cases 
of type 2 Diabetes Mellitus.  
Methodology 
All subjects were interviewed regarding a full medical history 
that included age, sex, occupation, duration and family history 
of diabetes mellitus. The general physical examination 
procedure included measurement of height, weight, waist 
circumference and hip circumference. Waist circumference at 
the umbilical level and hip circumference at the level of 
maximum girth were measured and waist –hip ratio (W/H) [6] 
were calculated, so also the Body Mass Index (BMI) [7] in each 
subject. The material for the study was the peripheral venous 
blood. Samples were drawn after 8 to 12 hour of overnight 
fast. Sample for plasma glucose estimation was collected in 
grey capped vaccutainer and others in yellow topped gel tube. 
All the tubes were subjected to centrifugation at 3000 rpm for 
10 minutes followed by storage at –40⁰C until assayed.  
Serum adiponectin was measured using sensitive ELISA (Assay 
Max Human adiponectin Elisa Kit (Catalog No: EA2500-1)) [8] . 
Fasting plasma glucose was measured by Hexokinase–
glucose-6-phosphate dehydrogenase method [9]. Triglyceride 
was measured by enzymatic method i.e. GPO - PAP (Glycerol 
phosphate oxidase – peroxidase – amidopyrine method) [10]. 
HDL cholesterol was measured by enzymatic end point 
method (Accelerator Selective Detergent methodology) [11]. 
RESULTS 
A highly significant reduction of serum adiponectin level in 
diabetic group (cases) compared to control / healthy group (p 
<0.01) was observed. There was highly significant difference 
of BMI & W/H between these two groups. A significant 
decrease in HDL –C (p< 0.010) in diabetic group was noticed. 
Triglyceride and fasting blood glucose were high in diabetic 
group but not statistically significant. [Table – 1] 
Table 1. Comparison of parameters of the study and control 
groups 
Parameter 
Control 
(n=50) 
Study group 
(n=110) 
P value 
Age( Year) 52.2 ± 7.6 55.24± 6.4 0.01* 
Sex (M/F) 25 / 25 44 / 66 --- 
BMI(Kg/m²) 25.63  ± 3.2 26.75 ± 4.2 0.001** 
W/H 0.89 ± .16 0.97 ± .1 0.004** 
Adiponectin 
(µg/ml) 
10.37 ± 7.7 7.53 ± 4.8 0.000** 
FBG (mg/dl) 100 ± 9.0 143 ± 66.7 0.079 
HDL(mg/dl) 36 ± 7.4 33 ± 11.8 0.01* 
TG(mg/dl) 114 ± 46.5 192± 100.4 0.163 
**highly significant (P < 0.01) * significant (P < 0.05) 
All the subjects in the study and control groups were further 
subdivided into two subgroups based on BMI (<25 and ≥25).   
As shown in Table – 2, waist hip ratio was higher in obese 
group which is statistically highly significant (p<0.000). 
Adiponectin was decreased in obese group but not 
statistically significant. On analyzing by Pearson correlation 
there was no correlation between BMI and the biochemical 
parameters such as serum adiponectin, FBG, serum HDL and 
TG in control group. 
Table 2. Comparison of parameters of control group based 
on BMI 
Parameter 
BMI < 25          
( n= 20 ) 
BMI ≥ 25         
( n= 30) 
P value 
W/H 0.79  ± 0.1 0.96  ±  0.2 0.000** 
Adiponectin 10.8  ±  9.4 10.08 ± 6.4 0.904 
FBG 97.8  ±  7.5 101.46± 9.7 0.190 
HDL 36  ±  8.7 36  ±  6.5 0.634 
TG 104  ±  46 121  ± 46 0.329 
**highly significant (P < 0.01) * significant (P < 0.05) 
On comparing the parameters in study group based on BMI, 
as shown in Table – 3, it was observed that waist hip ratio 
and serum triglyceride were significantly high in obese 
diabetic group. The adiponectin concentration was increased 
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in obese diabetic group compared to non obese diabetics but 
was not statistically significant attributed to high standard 
deviation and sample size. There was increase in TG and 
decrease in HDL between two groups but was not statistically 
significant.  
Table 3. Comparison of parameters of study group based on 
BMI 
Parameter 
BMI < 25              
(n = 39) 
BMI ≥ 25              
(n = 71) 
P value 
W/H 0.93  ±  0.1 0.99 ± 0.09 0.034* 
Adiponectin 6.44  ±  3.9 8.13  ±  5.19 0.079 
FBG 144 ±  69.8 143.5 ± 65.5 0.967 
HDL 36  ±  13 31.7  ±  10.8 0.067 
TG 159.6±65.9 210.1 ± 111 0.011 
**highly significant (P < 0.01) * significant (P < 0.05) 
Figure 1. Comparison of adiponectin based on BMI 
On correlation of BMI with biochemical parameters in control 
group, a negative correlation was obtained between BMI and 
serum adiponectin (R = - 0.023, P = 0.872). Analyzing the 
study group, a significant but positive correlation (R = 0.302, 
P = 0.001) was observed between BMI and serum 
adiponectin. But a significant negative correlation of BMI 
with serum HDL- C was noted although it was non-significant 
with FBG and TG.  
Table 4. Correlation of BMI with Adiponectin, FBG, serum 
creatinine, HDL and TG in control group 
Parameter Correlation coefficient P value 
Adiponectin -.023 0.872 
FBG .206 0.151 
HDL .050 0.729 
TG .167 0.246 
Table 5. Correlation of BMI with Adiponectin, FBG, serum 
creatinine, HDL and TG in study group 
Parameter Correlation coefficient P value 
Adiponectin .302 0.001** 
FBG .087 0.368 
HDL -.194 0.04* 
TG .144 0.133 
**highly significant (P < 0.01) * significant (P < 0.05) 
 A similar trend was also observed on analyzing W/H ratio 
with the biochemical parameters in both case and control 
groups. 
Table 6. Correlation of W/H with Adiponectin, FBG, Serum 
creatinine, HDL, TG in control group 
Parameter 
Correlation 
coefficient 
P value 
Adiponectin -.096 0.509 
FBG .185 0.199 
HDL .199 0.167 
TG .077 0.593 
Table 7. Correlation of W/H with Adiponectin, FBG, Serum 
creatinine, HDL and TG in study group 
Parameter 
Correlation 
coefficient 
P value 
Adiponectin .131 0.174 
FBG -.002 0.986 
HDL -.139 0.148 
TG .082 0.396 
DISCUSSION  
Adipocytes are an endocrine entity and secrete various 
proteins commonly referred to as adipocytokines. These 
include tumor necrosis factor, plasminogen-activator 
inhibitor type 1, adipsin, resistin, leptin, and adiponectin [12]. 
Most adipocytokines are positively correlated with obesity; 
however, adiponectin is negatively correlated with obesity 
and appears to be down-regulated in more obese patients. 
Adiponectin also plays an important role in glucose 
metabolism and insulin resistance and is down-regulated in 
type 2 diabetes patients and in those with cardiovascular 
disease [13, 14, 15]. In the present study, diabetic patients 
had a lower concentration of adiponectin compared with 
that of non-diabetic control group as published in our 
previous published article.  
Analysing the control group, a lower serum adiponectin level 
was observed in the subgroup with BMI more than 25 but it 
was not statistically significant possibly due to small sample 
size for statistical comparison. But the study group (cases) 
revealed a higher serum adiponectin level in the subgroup 
with BMI more than 25. This result is in contrast to the 
studies by Merja Santaniemi et al in 2006 [16], Drazenka 
Pongrac Barlovic et al in 2010 [17] and Arleta Malecha-
Jedraszek et al in 2011 [18]. As all diabetic patients in our 
study were of different duration of diabetes with or without 
various complications like hypertension, micro and 
macroalbuminuria and were under treatment, the excretion 
of adiponectin could be affected showing higher adiponectin 
in obese diabetic patients compared to non obese diabetic 
patients. 
The positive correlation observed between BMI and serum 
adiponectin was in contrast to reports by other authors 
including Merja Santaniemi et al in 2006 [16], Drazenka 
Pongrac Barlovic et al in 2010 [18]. The reason may be 
alteration in the blood concentration of adiponectin by 
various factors such as medication, exercise, diet, alcohol, 
smoking etc and most importantly excretion of adiponectin in 
later stage of diabetic nephropathy. 
0
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A negative correlation was observed on analyzing waist hip 
ratio (W/H) with serum adiponectin in control group but it 
was not statistically significant. Correlation of waist hip ratio 
with adiponectin level was found to be non-significant in the 
study group. A study by Mojtaba Eizadi et al in 2006 [19] also 
reveals a result similar to this study. But studies by Amir 
Elokely et al in 2010 [20], showed significant correlation of 
waist hip ratio with serum adiponectin which could be 
attributed to similar possible factors as mentioned in the 
context of BMI above. 
Adiponectin augment lipid oxidation with increased glucose 
uptake.  This results in prevention of postprandial elevation 
of FFA. gAd administration improves insulin sensitivity in 
muscle by increasing fatty acid oxidation with a reduction in 
myocellular lipid accumulation. Here in this study adiponectin 
levels have been positively associated with HDL-C and 
negatively with low-density lipoprotein-cholesterol and TG 
(4), suggesting a role not only in obesity but also in 
dyslipidemia. But in case of obese diabetic group though 
adiponectin was high but reverse finding may suggest 
improper function of it on lipid metabolism. 
CONCLUSION  
Serum adiponectin level decreases with obesity, with W/H 
and BMI as the comparison tools. But such relation is not 
seen in obesity with diabetes mellitus which could be due to 
defect in secretion as well as excretion of adiponectin in 
diabetic individuals and with diabetic complications. 
Adiponectin is lowered in obese non-diabetics affecting lipid 
metabolism showed by increase of LDL and TG and decrease 
of HDL. In obese diabetics adiponectin is high but 
dyslipidemia is still present possibly due to improper function 
of existing serum adiponectin. 
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